Open in interactive viewer → charts, metric popovers & call review

DarioHealth’s $13.1 Million Convergence Story Meets a 76% Collapse

A new chairman, a GLP-1 prescribing pivot, and a stock that has already voted against the ARR math.
DRIO · Earnings Call · 2026-11-12

A new chairman, a bigger theory

DarioHealth used its third-quarter call to introduce John Palumbo as chairman and to reframe the company not as a digital chronic-care vendor but as the path between consumer health and payer-funded chronic care. Palumbo, a 40-year health-care operator, argued that four forces are collapsing the wall between B2C and B2B2C: consumers choosing their own front door, pharma selling branded GLP-1 therapies direct, payers redesigning benefits around fixed upfront costs, and payers bringing consumer choice inside the benefit.

The convergence of business-to-consumer, B2C, and business-to-business-to-consumer, B2B2C is accelerating and bringing 2 large previously separate markets together.

John Palumbo, Chairman of the Board · 2026-11-12
That is the new narrative. The current keyword cluster — direct-to-consumer, narrow network, ASO business, sleep apnea — all hangs off it. But GLP-1 is not a new theme for Dario; it topped the company’s keyword list in 2025Q1 and 2024Q3. What is new is the apparatus around it: narrow networks, carve-outs, and the claim that payers will buy the therapy itself, not just the digital engagement around it. In the global top-75, GLP-1 does not appear this quarter, so this is not a market-wide editorial wave; it is a company-specific bet, albeit one a handful of recent reporters also mention. On the call, Lara Dodo described members entering through Dario’s digital front door, being screened to FDA guidelines, routed to a provider network, and then having scripts sent to Lilly or Novo or a pharmacy of choice. That is a more ambitious and more regulated business than the old engagement platform.

The quarter was better; the guide is still back-end loaded

Revenue was $5.3 million, up 6% year over year and 3% sequentially, with gross margin of 59% and operating expenses down 10%. Total revenue has been stuck in a $5 million-to-$8 million quarterly band for years, so the return to growth is real but small. Operating loss improved 15% year over year to $8 million, and gross margin held near 60%. Chen Franco said the company had $31.2 million in cash after its July registered direct offering and believed it had the resources to execute. “We believe we have the resources to execute on our priorities as contracted revenue is recognized and our new programs are implemented.” — Chen Franco-Yehuda, Unknown · 2026-11-12 But the acceleration keeps sliding right. For the New Jersey health plan win — about 1.5 million covered lives through Amwell — Lara Dodo was explicit: “we aren’t anticipating a lot in the first 2 halves of ’27. It’s probably in the back half of 2027 because the full socialization with the employees has not begun yet.” — Lara Dodo, Unknown · 2026-11-12 And Erez Raphael said the $13.1 million of contracted and late-stage ARR would convert into 2027 and also some of it in 2028. “this $13.1 million will be converted into 2027 and also some of it in 2028.” — Erez Raphael, Chief Executive Officer · 2026-11-12 That is not a Q4 event. It is a 2027-2028 promise.

The ARR math is the problem

The most important number on the call was not revenue. It was the definition of contracted ARR. In May 2026, Erez Raphael told investors: “we have $30 million worth of contracted ARR late-stage business.” — Erez Raphael, Chief Executive Officer · 2026-05-13 By the August call, the figure was $13.1 million: “we signed accounts with contracted ARR of $13.1 million that we believe that in a few quarters we’re going to gain this ARR in actual revenues.” — Erez Raphael, Chief Executive Officer · 2026-08-11 The third quarter repeated the $13.1 million. That is a huge shrink in a metric management itself introduced as the forward-looking anchor. It may reflect a tighter definition — the current call says more than 50% is not ASO — but the market does not get to see the bridge. The stock has already voted: DarioHealth fell 76.4% over the last 90 trading days and 74% in the last five weeks, with the shares peaking at $7.90 on July 22 and now sitting 79.1% below that level. This is a fresh report into a collapse, not a breakout. The breakeven target has moved too. In March 2026, Erez Raphael said the top line needed to reach $38 million to $42 million to get to cash-flow positive. “The overall top line that we see that will take us there is somewhere in the range of $38 million to $42 million in revenues.” — Erez Raphael, Chief Executive Officer · 2026-03-19 On the current call, the answer to “are we still on track for breakeven” was: “I think that we are in the trajectory to hit breakeven in 2028, yes.” — Erez Raphael, Chief Executive Officer · 2026-11-12 That is a pushout, and it sits awkwardly beside a $20.8 million market cap and a $31.2 million cash balance. Effective net cash was -$17 million at the June quarter, so the $31.2 million is raise-funded. When cash exceeds market cap, the market is not paying for the platform; it is discounting the burn.

What management stopped emphasizing

The keyword trail shows a genuine pivot. In 2026Q2, the company’s top themes were care delivery, health systems, outcome-based models, and clinical milestones. In 2026Q3, clinical care is a decliner and care delivery has fallen out of the top-30; the list is dominated by GLP-1, direct-to-consumer, ASO, narrow network, and contracted ARR. The care-delivery/health-system expansion announced in May has faded from the narrative; the new story is payer-funded GLP-1 therapy. That matters because Dario has now cycled through pharma services, health-system care delivery, and payer GLP-1 in short order. Each pivot is logically adjacent, but each one resets the proof clock. There are real positives. More than 80% of contracted and late-stage recurring revenue is now multi-condition, versus 50% of new client wins in the prior-year period. DarioIQ, the AI engagement layer, is now claimed to add up to roughly 14% to engagement-based ARR from existing customers, versus the prior 10%-15% expectation. Channel partners account for about 75% of new accounts. Those are the kinds of operating metrics that could matter if the revenue base were larger. But at $5.3 million a quarter, they are still rounding errors against the $2.2 trillion chronic-disease spend pool Palumbo cited.

Why it matters

DarioHealth is a $20.8 million market-cap company with $31.2 million of cash, trying to convince investors that it can be the neutral path between consumers and payers in chronic care. If the convergence is real, the option value is large. But the evidence today is a $5.3 million quarterly revenue base, a $13.1 million contracted/late-stage ARR figure that shrank from a $30 million claim, and a stock down 76% in 90 days. The burden is on execution: convert ASO contracts, launch New Jersey, and show GLP-1 care-delivery revenue before the cash pile is consumed. Until then, the market is treating the grand convergence as a narrative, not a number.